Loading stock data…
Profound Medical Corp. (PROF)
$6.59+0.09 (+1.38%)
After Hours$6.59+0.00 (+0.00%)· Last close Jun 29
Profound Medical Corp.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Profound Medical Corp. in the Healthcare sector is trading at $6.59 with a market capitalization of $242M. Wall Street consensus targets $11.14 (5 analysts), implying a +69.0% move over the next 12 months. The stock is currently 26% below its 52-week high of $8.95, remaining 0.9% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +69.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.34M↓ | $5.98M↑ | $5.29M↑ | $2.21M↓ | $2.62M |
| Gross Profit | $3.83M↓ | $3.99M↑ | $3.93M↑ | $1.62M↓ | $1.85M |
| Operating Income | -$8.02M↓ | -$7.37M↑ | -$8.91M↑ | -$13.81M↓ | -$11.17M |
| Net Income | -$7.05M↑ | -$8.18M↓ | -$7.98M↑ | -$15.70M↓ | -$10.72M |
Peer Comparison
JNJUNHPFE
Fundamentals
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO sy...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$242.37M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-65.46%
Volume
Today's trading volume
29,349
Recent News
Profound Medical Corp. (PROF) Dropped Despite High Potential
Grow Funds, an investment Advisor, released its Q1 2026 investor letter for “GROW Small Cap Equity Long/Short Fund”. A copy of the letter can be downloaded here. In Q1 2026, GROW Small Cap Equity Long/Short L.P (Fund) returned 4.18%, outperforming the Russell 2000 Growth Index’s –2.80%, HFRI Equity Hedge Index’s -0.24%, and the HFRI Fundamental […]
Wall Street Analysts See a 59.68% Upside in Profound Medical (PROF): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 59.7% in Profound Medical (PROF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Profound Medical Q1 Earnings Call Highlights
Profound Medical (NASDAQ:PROF) reported sharply higher first-quarter revenue and reiterated its view that adoption of its TULSA prostate treatment platform is moving toward broader commercial use, supported by new clinical data, payer progress and a growing installed base. For the three months ende
Profound Medical (PROF) Reports Q1 Loss, Tops Revenue Estimates
Profound Medical (PROF) delivered earnings and revenue surprises of +21.91% and +4.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical Down 8.5% After Hours as Its Q1 Loss Narrows, Revenue More Than Doubles, Beats Estimates
Profound Medical (PRN.TO, PROF) was last seen down 8.5%% in after-hours New York trade after the com